oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 in Patients with Obesity-Related Heart Failure and Type 2 Diabetes Oral Semaglutide at a Dose

Approximately one in four patients taking Wegovy experience constipation, which occurs due to slowed intestinal transit time

Its likely not IBS and needs prompt evaluation

Increased Satiety : They act on brain receptors to enhance feelings of fullness, leading to reduced food intake

Used Wegovy pens and needles should be placed in a sharps container and disposed of according to local pharmacy or healthcare guidance

Patients should be aware of costs (often $500$2,500 per treatment) and downtime (typically minimal)

Semaglutide (Wegovy and Ozempic): Weekly GLP-1 injection Semaglutide is an FDA-approved GLP-1 receptor agonist that mimics the activity of the natural hormone GLP-1, which regulates hunger and appetite